Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ULK1 | O75385 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 3/20 | 0.46 |
| ▸ | JAK1 | P23458 | 3/20 | 0.46 |
| ▸ | LRRK2 | Q5S007 | 11/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | ITK | Q08881 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22445921 | 0.85 | MLLT1 (0.49) | ULK1JAK2JAK1LRRK2NAMPT | |
| SCHEMBL22445877 | 0.82 | MLLT1 (0.47) | ULK1JAK2JAK1LRRK2NAMPT | |
| SCHEMBL22445917 | 0.75 | ULK1 (0.48) | ULK1JAK2JAK1LRRK2NAMPT | |
| SCHEMBL12286618 | 0.75 | JAK2 (0.63) | ULK1JAK2JAK1LRRK2NAMPT | |
| SCHEMBL22445848 | 0.74 | MLLT1 (0.66) | ULK1JAK2JAK1LRRK2NAMPT | |
| SCHEMBL18167981 | 0.73 | JAK2 (0.52) | ULK1JAK2JAK1LRRK2ITK | |
| SCHEMBL22453795 | 0.73 | LRRK2 (0.40) | ULK1JAK2JAK1LRRK2 | |
| SCHEMBL31147795 | 0.73 | NPC1 (0.57) | ULK1JAK2JAK1LRRK2NAMPT | |
| SCHEMBL14014041 | 0.72 | ITK (0.57) | JAK2JAK1ITKKDM4E | |
| SCHEMBL22445841 | 0.72 | LRRK2 (0.70) | ULK1JAK2JAK1LRRK2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020191261-A1 | INDAZOLES AS LRRK2 INHIBITORS | E-SCAPE BIO, INC. (US) | 2020-09-24 | — | — | WO | claimed |
| US-20220162192-A1 | INDAZOLES AS LRRK2 INHIBITORS | ESCAPE Bio, Inc. | 2022-05-26 | — | — | US | disclosed |
| WO-2020191261-A1 | INDAZOLES AS LRRK2 INHIBITORS | E-SCAPE BIO, INC. (US) | 2020-09-24 | — | — | WO | disclosed |
| WO-2020191261-A1 | INDAZOLES AS LRRK2 INHIBITORS | E-SCAPE BIO, INC. (US) | 2020-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220162192-A1 | INDAZOLES AS LRRK2 INHIBITORS | LRRK2, PARK7, PINK1 | ULK1 187/4885JAK2 2201/4885JAK1 1985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.